← Leaderboards
Michael A Bookman
Fox Chase Cancer Center
$1,846,719
Attributed
$3,117,600
Total exposure
4
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $785.4K · FY2009–13$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$3,117,600 · 4
By mechanism
P50$2,332,728 · 2
P30$784,872 · 2
Top collaborators
- Paul Cairns5 shared
- Mark Aloysius Morgan5 shared
Most similar at Fox Chase Cancer Center
Same institution · by research overlap
- Andrew K Godwin$21,382,895
- Thomas C Hamilton$7,664,005
- Joseph Robert Testa$17,947,194
- Louis M Weiner$35,160,146
- Lori J Goldstein$4,869,349
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsBiomedical FacilityHealth Science Research Analysis /EvaluationPatient /Disease RegistryHuman DataClinical ResearchBiomedical ResourceBlood TestsBloodBiomarkerCancer PatientCancer TypeCarboplatinCellsCancer BiologyCohortBiologyBrca2 GeneClassificationCombination ChemotherapyCancer CellDefectDetectionChemotherapy
Grant awards (21)
Gene Methylation Signatures for Predictive Classification of Response to Therapy$279,486
P50 · FY2013 · CA
Gene Methylation Signatures for Predictive Classification of Response to Therapy$785,372
P50 · FY2012 · CA
Gene Methylation Signatures for Predictive Classification of Response to Therapy$289,614
P50 · FY2011 · CA
Gene Methylation Signatures for Predictive Classification of Response to Therapy$304,215
P50 · FY2010 · CA
Gene Methylation Signatures for Predictive Classification of Response to Therapy$247,635
P50 · FY2009 · CA
CORE--PROTOCOL REVIEW AND MONITORING SYSTEM$196,218
P30 · FY2002 · CA
CORE--PROTOCOL MANAGEMENT$196,218
P30 · FY2002 · CA
Pharmacokinetic models to design &optimize clinical trials in ovarian cancer$165,355
P50 · FY2002 · CA
CORE--PROTOCOL MANAGEMENT$196,218
P30 · FY2001 · CA
CORE--PROTOCOL REVIEW AND MONITORING SYSTEM$196,218
P30 · FY2001 · CA
Pharmacokinetic models to design &optimize clinical trials in ovarian cancer$165,355
P50 · FY2001 · CA
CORE--PROTOCOL REVIEW AND MONITORING SYSTEM$0
P30 · FY2001 · CA
CORE--PROTOCOL MANAGEMENT$0
P30 · FY2001 · CA
CORE--PROTOCOL MANAGEMENT$0
P30 · FY2001 · CA
CORE--PROTOCOL REVIEW AND MONITORING SYSTEM$0
P30 · FY2001 · CA
Pharmacokinetic models to design &optimize clinical trials in ovarian cancer$47,848
P50 · FY2000 · CA
Pharmacokinetic models to design &optimize clinical trials in ovarian cancer$47,848
P50 · FY2000 · CA
CORE--PROTOCOL MANAGEMENT$0
P30 · FY2000 · CA
CORE--PROTOCOL REVIEW AND MONITORING SYSTEM$0
P30 · FY2000 · CA
CORE--PROTOCOL REVIEW AND MONITORING SYSTEM$0
P30 · FY2000 · CA
CORE--PROTOCOL MANAGEMENT$0
P30 · FY2000 · CA